2. Search Result
Search Result
Results for "

Oxalate Oxidase

" in MedChemExpress (MCE) Product Catalog:

5

Inhibitors & Agonists

2

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-132613
    Lumasiran sodium

    		Small Interfering RNA (siRNA) Metabolic Disease
    Lumasiran sodium, an investigational RNA interference (RNAi) therapeutic agent, reduces hepatic oxalate production by targeting glycolate oxidase. Lumasiran sodium reduces urinary oxalate excretion, the cause of progressive kidney failure in primary hyperoxaluria type 1 (PH1) .
    Lumasiran sodium
  • HY-E70385
    Oxalate Oxidase

    		Endogenous Metabolite Others
    Oxalate Oxidase, or oxalate oxidase, catalyzes the oxidation of oxalic acid to hydrogen peroxide and carbon dioxide in the presence of oxygen. Oxalate Oxidase can be found in a variety of plants (such as barley) and microorganisms and can be used to treat wastewater and filtrates containing oxalic acid .
    Oxalate Oxidase
  • HY-132588
    Lumasiran

    ALN-G01

    		 Small Interfering RNA (siRNA) Metabolic Disease
    Lumasiran (ALN-G01), a siRNA product, reduces hepatic oxalate production by targeting glycolate oxidase. By silencing the gene encoding glycolate oxidase, Lumasiran depletes glycolate oxidase and thereby inhibits the synthesis of oxalate, which is the toxic metabolite that is directly associated with the clinical manifestations of Primary hyperoxaluria type 1 (PH1) .
    Lumasiran
  • HY-W176012
    Glycolate oxidase-IN-1

    		Others Metabolic Disease
    Glycolate oxidase-IN-1(compound 26), a salicylic acid derivative, is a glycolate oxidase (GO) inhibitor with an IC50 of 38.2 μM. Glycolate oxidase-IN-1 has the ability to reduce oxalate production in hyperoxalate hepatocytes and can be used in the study of primary hyperoxaluria type 1 (PH1) .
    Glycolate oxidase-IN-1
  • HY-148610
    LDH-IN-2

    		Others Metabolic Disease
    LDH-IN-2, a salicylic acid derivative, is an inhibitor of glycolate oxidase (GO). LDH-IN-2 decreases oxalate output in hyperoxaluric hepatocytes. LDH-IN-2 can be used for research of primary hyperoxaluria type 1 (PH1) .
    LDH-IN-2

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: